We’re proud to support our partners at CURITY Pharma as they embark on a groundbreaking journey in medical cannabis cultivation — aligned with GACP and GMP standards and driven by science, compliance, and compassion.
This milestone marks more than the launch of a cultivation facility — it signals a new era of evidence-based cannabinoid therapy. From scientific cultivation under strict GACP (Good Agricultural and Collection Practices) protocols to GMP-compliant (Good Manufacturing Practices) processing, every step is designed with one purpose: improving patient outcomes.
Innovation at the core of cultivation
Full regulatory compliance with European and global standards
Unwavering commitment to patients and ethical progress
At Impactus ESG, we believe in championing ventures that combine vision with responsibility. We back projects that not only push boundaries, but also build trust through transparency and long-term sustainability.
This partnership with CURITY Pharma reflects our shared belief in holistic, patient-first healthcare — one that embraces nature, leverages science, and upholds the highest ethical benchmarks.
Together, we are:
Advancing next-generation therapies through phytopharmaceutical innovation
Promoting sustainability in healthcare by aligning with ESG principles
Building trust across patients, professionals, and regulators
Here’s to setting new standards in cannabinoid science, empowering healthcare systems, and bringing real change to people’s lives — one plant, one process, one patient at a time.
